Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP raised its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 46.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,813 shares of the company's stock after purchasing an additional 22,096 shares during the period. Wellington Management Group LLP owned 0.10% of Kiniksa Pharmaceuticals worth $1,381,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter worth approximately $61,000. KLP Kapitalforvaltning AS purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter worth $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at $160,000. Tower Research Capital LLC TRC raised its stake in shares of Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after acquiring an additional 719 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, insider Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. This trade represents a 65.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. The trade was a 25.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 391,014 shares of company stock valued at $10,101,143 in the last ninety days. Corporate insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Stock Down 1.8%

KNSA stock traded down $0.56 during trading on Tuesday, hitting $29.77. The company had a trading volume of 561,586 shares, compared to its average volume of 506,796. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $17.38 and a 52-week high of $30.68. The company has a 50 day simple moving average of $24.60 and a 200-day simple moving average of $22.03. The firm has a market capitalization of $2.17 billion, a P/E ratio of -212.63 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period last year, the company posted ($0.25) earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

KNSA has been the topic of several analyst reports. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Citigroup started coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.